Pharmacopeia, Inc. (NASDAQ: PCOP), a clinical development stage biopharmaceutical company, is focused on discovering and developing innovative small molecule therapeutics to attend to significant medical needs. The company’s broad portfolio of clinical and preclinical candidates are currently under development internally or with partners, including nine clinical compounds in Phase 2 or Phase 1 development. For further information, visit the Company’s web site at www.pcop.com.
- 17 years ago
QualityStocks
Pharmacopeia, Inc. (NASDAQ: PCOP)
Tags Rodman & Renshaw
Related Post
-
Soligenix Inc. (NASDAQ: SNGX) Driving Innovation in Photodynamic Therapy Potential in Oncology, Dermatology
One of the key advantages of photodynamic therapy is its selectivity. Soligenix is advancing HyBryte(TM),…
-
Perpetuals.com Ltd. (NASDAQ: PDC) Targets the Regulated Bridge Between Traditional Markets and Blockchain Infrastructure
Perpetuals.com focuses on 24/7, self-clearing trading venues that remove reliance on traditional clearing houses, representing…
-
ESGold Corp. (CSE: ESAU) (OTCQB: ESAUF) Marks Pivotal Milestone with Completed and Delivered Comprehensive ANT-Based 3D Geological Model for Montauban
Disseminated on behalf of ESGold Corp. (CSE: ESAU) (OTCQB: ESAUF) and may include paid advertising.…